Ipsen Biopharmaceuticals
Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Ipsen Biopharmaceuticals
Expert Experience on mPDAC: 1L Treatment Planning & Monitoring Disease Progression
FEATURING
Tara Seery
- 381 views
- October 5, 2021
Ipsen Biopharmaceuticals
Managing mPDAC: Overview of the Disease State, Clinical Presentation, Available Treatments and More
FEATURING
Arturo Loaiza-Bonilla
- 290 views
- October 6, 2021
- 1